CARA

Dopo l'orario di chiusura: .30 -0.008 -2.60%

Cara Therapeutics Inc (CARA)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Cara Therapeutics Inc Stock (CARA) Company Profile

Cara Therapeutics Inc

203-406-3700

400 ATLANTIC STREET, SUITE 500, STAMFORD, CT

Prossima data di guadagno

Ultimi documenti SEC

CARA's Discussions on Twitter

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-03-08	Downgrade	BofA Securities	Neutral → Underperform
2022-03-08	Aggiornamento	JP Morgan	Neutral → Overweight
2021-11-01	Ripresa	Canaccord Genuity	Buy
2021-08-03	Iniziato	JP Morgan	Neutral
2020-04-21	Reiterato	H.C. Wainwright	Buy
2019-08-12	Reiterato	H.C. Wainwright	Buy
2019-05-29	Reiterato	Laidlaw	Buy
2019-02-06	Ripresa	Jefferies	Buy
2019-01-15	Iniziato	BofA/Merrill	Neutral
2018-09-21	Iniziato	Cantor Fitzgerald	Overweight
2018-09-13	Iniziato	Jefferies	Buy
2018-08-08	Reiterato	Stifel	Buy
2018-06-28	Reiterato	H.C. Wainwright	Buy
2018-03-12	Ripresa	H.C. Wainwright	Buy
2018-02-12	Aggiornamento	Janney	Neutral → Buy
2018-01-19	Iniziato	Seaport Global Securities	Buy
2017-06-30	Downgrade	Janney	Buy → Neutral
2017-06-30	Reiterato	Laidlaw	Buy
2017-06-30	Reiterato	Stifel	Buy
2017-03-28	Reiterato	H.C. Wainwright	Buy
2017-03-28	Reiterato	Laidlaw	Buy
2017-03-10	Reiterato	Laidlaw	Buy
2016-10-13	Iniziato	H.C. Wainwright	Buy
2016-08-08	Reiterato	Needham	Buy

Mostra tutto

Cara Therapeutics Inc Borsa (CARA) Ultime notizie

Cara Therapeutics Inc Azioni (CARA) Dati Finanziari

Cara Therapeutics Inc (CARA)

Cara Therapeutics Inc Stock (CARA) Company Profile

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

Cara Therapeutics Inc Borsa (CARA) Ultime notizie

Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex

Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World

Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World

Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace

A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News

Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR

Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada

Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com

Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Carmat launches capital increase, stock plummets - Marketscreener.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire

What technical indicators reveal about CARA stock - US Post News

The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News

Cara Therapeutics Inc (CARA)’s Day in Review: Closing at 0.26, Down by -2.85 - The Dwinnex

CARA’s Stock Market Adventure: -62.18% YTD Growth Amidst Volatility - The InvestChronicle

How to interpret Cara Therapeutics Inc (CARA)’s stock chart patterns - US Post News

Pruritus Therapeutics Market Competition & Segment Analysis – Actavis Plc, Amgen Inc., Bristol-Myers Squibb, Cara Therapeutics, Cipla – Cauverynews - Cauverynews

Metric Deep Dive: Understanding Cara Therapeutics Inc (CARA) Through its Ratios - The Dwinnex

Pruritus Pipeline Analysis 2024: FDA Approvals and Emerging - openPR

Does Cara Therapeutics Inc (CARA) offer a good opportunity for investors? - SETE News

Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World

Following more layoffs, Stamford’s Cara Therapeutics considers ‘strategic alternatives,’ including dissolving company - Hartford Business Journal

Analysts review Cara Therapeutics Inc’s rating - Knox Daily

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Rating of “Hold” by Brokerages - Defense World

Vanguard Group Inc. Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World

CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace

Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World

Cara Therapeutics (NASDAQ:CARA) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS - Defense World

Cara: Q2 Earnings Snapshot - San Antonio Express-News

Cara: Q2 Earnings Snapshot - The Washington Post

Cara: Q2 Earnings Snapshot - Milton Daily Standard

Cara: Q2 Earnings Snapshot - Thehour.com

Investing in Cara Therapeutics Inc (CARA) Is Getting More Attractive - Knox Daily

Understanding the Risks of Investing in Gain Therapeutics Inc (GANX) - Knox Daily

Cara Therapeutics receives Nasdaq compliance extension - Investing.com India

Cara Therapeutics CEO sells over $1,400 in stock - Investing.com India

Cara Therapeutics receives Nasdaq compliance extension By Investing.com - Investing.com Australia

Cara Therapeutics CEO sells over $1,400 in stock - Investing.com

Cara Therapeutics receives Nasdaq compliance extension - Investing.com

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Taking the lead: Cara Therapeutics Inc (CARA) - SETE News

Cara Therapeutics Inc (CARA) deserves deeper analysis - US Post News

CT-based bioscience firm Cara Therapeutics eliminates most of workforce, filing indicates - CT Insider

5 Biotechs That May Surge On Takeovers - Investopedia

Medical Marijuana Market Growth Drivers | Cannabis Sativa, Inc.; Cara Therapeutics Inc., Inc.; United Cannabis Corporation – Economica - Economica

Cara Therapeutics (NASDAQ:CARA) Share Price Passes Below 200 Day Moving Average of $0.65 - Defense World

Recent Insider Activity Could Benefit Cara Therapeutics Inc (CARA) - Knox Daily

Cara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.com - Defense World

These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers' - MSN

Sarcoma Therapeutics Market Is Booming Worldwide | Agenus, Agios, Eisai - openPR

Insider Selling: Posner Christopher, Cara Therapeutics Inc [CARA] PRESIDENT AND CEO divested 3,936 shares - Knox Daily

Cara Therapeutics Inc Azioni (CARA) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a CARA